We are pleased to announce that the PeerVoice activity entitled ''Advances in Adjuvant Melanoma Therapy: Working Together To Improve Outcomes’’ has now launched online. SYSF is proud to endorse this work, and applauds the valuable work put into this educational resource. This initiative features two expert...
We are happy to share with you the launch of chapter 1 of a new Uveal Melanoma Disease Education Campaign website by Immunocore, thinkuvealmelanoma.com. (Note: Please use Google Chrome for the best user experience). We are pleased to endorse this website and to share it...
Friday, February 15, 2019 10am EST | 7am PST With Presenters: Dr. Marcus Butler, Princess Margaret Cancer Centre, Toronto, Ontario, Canada Dr. Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles, California Nigel Deacon, Ocular Melanoma Survivor/Patient, British Columbia, Canada This webinar provides an update on the landscape of...
Ocular Melanoma - Innovative Treatments and Beyond With Presenters: Dr. Marcus Butler, Princess Margaret Cancer Centre, Toronto, Ontario, Canada Dr. Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles, California Nigel Deacon, Ocular Melanoma Survivor/Patient, British Columbia, Canada This webinar provides an update on the landscape of metastatic ocular...
Dr. Joel Claveau, Medical Oncologist, will review the latest news, clinical data and other updates as they relate to melanoma treatment in the adjuvant setting, presented at the American Society of Clinical Oncology (ASCO) Annual Meeting that took place in June 2018 in Chicago, Illinois and the European...
We are happy to announce the launch of an informative website about clinical trials by another of our supporting partners. F. Hoffmann-La Roche Ltd. has put together a website called ForPatients, which includes a search tool for finding clinical trials in various cancer indications, plus...
Join us for this free webinar, which reviews the latest news and clinical data related to melanoma treatment in the adjuvant setting, as presented in the 2018 conference season. 'Adjuvant' refers to patients with a stage II or stage III diagnosis. The majority of adjuvant patients typically undergo...
On September 26, 2018, you may have seen a special insert in the paper version of the National Post across the country, featuring eight pages of informative articles about immunotherapy, an innovative treatment proving successful in several cancer indications. This special content is the result...
In September 2018, Save Your Skin Foundation (SYSF) conducted an anonymous survey of melanoma patients in the adjuvant setting (diagnosed at a stage lesser than stage IV). This survey, titled "Melanoma Treatments in the Adjuvant Setting," was open globally, and we received responses from all...
We are excited to announce that one of our partners, Merck, has launched an informative new website dedicated to educating the public about immuno-oncology. “Redefining Cancer Treatment” is an apt title for the topic: what is cancer immunotherapy, and how does it work, exactly? These questions...
